Company analysis: Bayer

Summary

Bayer AG (BAYN; reporting currency EUR) is a diversified life-science group with three operating segments: Pharmaceuticals (prescription medicines), Consumer Health (OTC), and Crop Science (seeds & traits and crop protection). Its core competencies are (1) R&D and commercialization in specialty pharma (notably oncology/cardiology/renal), (2) global branded OTC distribution, and (3) integrated agricultural inputs with scale manufacturing and a broad channel footprint. The investment case is currently dominated by litigation cash costs and balance-sheet flexibility rather than near-term top-line acceleration. Market position is strong in Crop Science by global scale and portfolio breadth, while Pharmaceuticals’ competitive advantage is concentrated in a smaller set of growth drivers (management highlighted products such as Nubeqa and Kerendia as key growth contributors). However, the group’s competitive positioning is structurally constrained by (a) elevated net financial debt and (b) persistent U.S. litigation over glyphosate (Roundup) and other legacy exposures, which has depressed reported earnings and investor risk appetite. In the most recent reporting cycle (FY 2025 results released March 2026), Bayer reported Group sales of €45.575bn (+1.1% currency/portfolio adjusted) and EBITDA before special items of €9.669bn (-4.5%). Core EPS was €4.91 (-2.8%). Reported net income was -€3.620bn, driven by high special charges largely related to litigation. Free cash flow (FCF) was €2.084bn and net financial debt ended 2025 at €29.843bn (down ~€2.8bn YoY). Bayer proposed a €0.11 dividend per share, underscoring a capital-allocation stance focused on deleveraging and cash preservation. (bayer.com) Key recent developments (last ~2 months) include a proposed Roundup class settlement agreement announced February 17, 2026, and subsequent court process updates, alongside a U.S. Supreme Court hearing scheduled for April 27, 2026 on a labeling/preemption-related case that management frames as central to containing future claims. Bayer’s 2026 outlook calls for broadly stable sales and earnings (FX-adjusted), but with FCF “heavily impacted” by litigation-related payouts; Bayer indicates litigation payouts of ~€5bn in 2026, implying negative FCF guidance for 2026 in some summaries of management commentary. (bayer.com) Valuation metrics are complicated by negative reported earnings (making trailing P/E not meaningful). On operating multiples, third-party screens around March 2026 show EV/EBITDA in the high-single digits (methodology-dependent). Investors should therefore anchor on (1) management’s 2026 EBITDA before special items guidance (€9.1–€9.6bn) and core EPS guidance (€4.00–€4.50, per Bayer’s updated methodology), and (2) the litigation-driven cash profile and debt trajectory. Near-term (0–12 months) performance is likely to be driven by legal/cash-flow milestones and FX, while the medium-term (12–36 months) hinges on restoring sustainable FCF and reducing headline litigation uncertainty. (bayer.com)

Key Takeaways

1. FY 2025 operating performance was resilient at the EBITDA level (EBITDA before special items €9.669bn) but reported profitability remained deeply negative due to litigation-related special charges (net income -€3.620bn). (bayer.com)
2. Net financial debt improved in 2025 to €29.843bn, but 2026 is expected to be cash-flow constrained by litigation payouts (Bayer indicates ~€5bn planned litigation-related payouts in 2026). (reports.bayer.com)
3. 2026 guidance implies stability rather than growth: sales €44–€46bn, EBITDA before special items €9.1–€9.6bn, and core EPS €4.00–€4.50 (updated methodology). (bayer.com)
4. The Roundup overhang remains the primary catalyst set: a proposed class settlement announced Feb 17, 2026 and a Supreme Court hearing scheduled for Apr 27, 2026 are central near-term events for risk repricing. (bayer.com)
5. Dividend is minimal (€0.11/share proposed), signaling that deleveraging and litigation funding take priority over shareholder distributions in the near term. (bayer.com)

Action Ideas

Contrarian Insights

• • Consensus often frames Bayer as primarily a litigation story; a contrarian (but still data-grounded) view is that the company’s operating base is more stable than headline net losses imply: FY 2025 delivered €45.575bn sales and €9.669bn EBITDA before special items, and 2026 guidance targets similar operating levels. This stability can matter if legal uncertainty declines, because valuation can re-rate on a lower risk premium even without strong growth. (bayer.com)
• • Another contrarian angle is that the market may over-focus on the existence of a settlement headline and under-focus on the cash-flow timing: Bayer indicates ~€5bn litigation-related payouts in 2026 and expects FCF to be heavily impacted. Even if legal pathways improve, the near-term funding requirement can keep equity returns capped until leverage and cash conversion normalize. (reports.bayer.com)